Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Controlled, Multicenter, Efficacy and Safety Study of Oral BGS649 vs. Placebo (Each Co-administered With a Combined Oral Contraceptive) Assessing Pain Response in Patients With Refractory Endometriosis

NCT01116440 is registered in ClinicalTrials.gov with Mereo BioPharma as lead sponsor.

NCT NCT01116440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01116440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Controlled, Multicenter, Efficacy and Safety Study of Oral BGS649 vs. Placebo (Each Co-administered With a Combined Oral Contraceptive) Assessing Pain Response in Patients With Refractory Endometriosis
Lead sponsor
Mereo BioPharma
Phase
Phase 2
Overall status
Terminated
Start date
April 15, 2010
Completion date
March 21, 2012
Enrollment
27 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

pelvic pain associated with refractory endometriosis